| 引用本文: |
梁婷, 邓云方, 钟辉, 刘琴, 陈光宇, 李亮.基于代谢组学探讨桃红方对高盐血瘀大鼠的改善作用[J].湖南中医药大学学报,2026,46(10):1991-2007[点击复制] |
|
| |
|
|
| 本文已被:浏览 276次 下载 565次 |
| 基于代谢组学探讨桃红方对高盐血瘀大鼠的改善作用 |
| 梁婷,邓云方,钟辉,刘琴,陈光宇,李亮 |
| (湖南中医药大学湖南省药食同源功能性食品工程技术研究中心, 湖南 长沙 410208;湖南中医药大学中医心肺病证辨证与药膳食疗重点研究室, 湖南 长沙 410208;湖南中医药大学中医诊断学湖南省重点实验室, 湖南 长沙 410208;湖南中医药大学中医学院, 湖南 长沙 410208) |
| 摘要: |
| 目的 探究桃红方对高盐血瘀大鼠的改善作用及机制。方法 采用超高效液相色谱-四极杆-飞行时间串联质谱(UPLC-Q-TOF-MS/MS)鉴定桃红方化学成分。采用高盐饮食喂养法建立高盐血瘀模型,将36只雄性SD大鼠随机分为空白组、模型组、阿司匹林组及桃红方低、中、高剂量组,每组6只。造模周期为30 d,于造模第17天起同步给药,各给药组灌胃药物治疗14 d。观察大鼠舌质颜色、尾部及爪甲色泽等血瘀表征变化,血液流变学检测大鼠的全血黏度、血浆黏度及纤维蛋白原,HE染色观察冠状动脉组织病理变化;网络药理学预测桃红方活性成分及血瘀证相关靶点,构建蛋白质-蛋白质(PPI)网络,通过GO和KEGG富集分析,筛选桃红方改善血瘀证的重要信号通路;利用UPLC-Q-TOF-MS/MS进行血清代谢组学分析,筛选差异代谢物并富集关键代谢通路,构建“代谢物-靶点基因”调控网络;采用ELISA检测血清中白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、细胞间黏附分子-1(ICAM-1)、血管细胞黏附分子-1(VCAM-1)、血栓调节蛋白(TM)、核因子κB亚基1(NF-κB1)、丝氨酸蛋白酶抑制剂家族E成员1(SERPINE1)、基质金属蛋白酶-9(MMP-9)、表皮生长因子受体(EGFR)、一氧化氮(NO)、白蛋白(ALB)水平,免疫组化检测心脏及肾脏组织中花生四烯酸5-脂加氧酶(ALOX5)和核因子κB(NF-κB)蛋白表达水平。结果 桃红方经鉴定含有黄酮类、有机酸类等71种成分。与空白组比较,模型组大鼠出现舌质紫暗、皮下瘀血等血瘀症状,全血黏度(低、中、高切变率)、血浆黏度及纤维蛋白原水平均显著升高(P<0.001);冠状动脉内中膜增厚、管腔内径增大、内膜和外膜脱落、细胞排列紊乱及心肌细胞水肿;大鼠血清中IL-6、TNF-α、ICAM-1、VCAM-1、TM、NF-κB1、SERPINE1、MMP-9及EGFR水平均显著升高(P<0.001),NO水平升高(P<0.05),ALB水平显著降低(P<0.001);心脏及肾脏组织中ALOX5与NF-κB蛋白表达水平均显著升高(P<0.001)。与模型组比较,桃红方低、中、高剂量组及阿司匹林组大鼠的舌质色泽、尾部及爪甲瘀血症状均呈现不同程度的改善,全血黏度(低、中、高切变率)、血浆黏度和纤维蛋白原水平均显著降低(P<0.001);桃红方低、中、高剂量组及阿司匹林组IL-6、TNF-α、EGFR、MMP-9、NF-κB1、ICAM-1、VCAM-1、SERPINE1、TM水平均降低(P<0.05,P<0.01,P<0.001),桃红方低、高剂量组ALB水平升高(P<0.001),阿司匹林组ALB、NO水平降低(P<0.05,P<0.01);心脏及肾脏组织中,桃红方低、中、高剂量组及阿司匹林组的ALOX5和NF-κB蛋白表达水平均显著降低(P<0.01,P<0.001)。与桃红方低剂量组比较,桃红方中、高剂量组的全血黏度(低、中、高切变率)、血浆黏度和纤维蛋白原水平均降低(P<0.05);桃红方中、高剂量组、阿司匹林组IL-6、TNF-α、EGFR、NF-κB1、ICAM-1、SERPINE1水平均显著降低(P<0.05,P<0.01,P<0.001),阿司匹林组MMP-9水平升高(P<0.05),桃红方中剂量组、阿司匹林组ALB水平显著降低(P<0.001),桃红方高剂量组、阿司匹林组VCAM-1、TM水平显著降低(P<0.01,P<0.001),阿司匹林组NO水平显著降低(P<0.001)。心脏及肾脏组织中,桃红方中、高剂量组及阿司匹林组ALOX5和NF-κB蛋白表达水平均显著降低(P<0.01,P<0.001)。与桃红方中剂量组比较,桃红方高剂量组、阿司匹林组IL-6、TNF-α、EGFR、NF-κB1、ICAM-1、VCAM-1、SERPINE1水平均降低(P<0.05,P<0.01,P<0.001),桃红方高剂量组ALB水平显著升高(P<0.001),桃红方高剂量组MMP-9水平显著降低(P<0.05),中剂量组MMP-9水平显著升高(P<0.001),阿司匹林组TM、NO水平均显著降低(P<0.01,P<0.001)。心脏及肾脏组织中,桃红方高剂量组及阿司匹林组ALOX5和NF-κB蛋白表达水平均降低(P<0.05,P<0.01,P<0.001)。与桃红方高剂量组比较,阿司匹林组IL-6、TNF-α、ALB、ICAM-1、VCAM-1、TM、NO水平均降低(P<0.05,P<0.01,P<0.001),MMP-9水平显著升高(P<0.001)。心脏组织中阿司匹林组ALOX5蛋白表达水平均显著降低(P<0.05),肾脏组织中阿司匹林组NF-κB蛋白表达水平均显著降低(P<0.01)。网络药理学筛选出桃红方与血瘀证的178个共同靶点,富集于脂质与动脉粥样硬化、磷脂酰肌醇3-激酶(PI3K)-蛋白激(Akt)等信号通路;代谢组学鉴定出24个差异代谢物,与空白组比较,模型组二十碳五烯酸(EPA)及其下游代谢产物5-羟基二十碳五烯酸(5-HEPE)、12-羟基二十碳五烯酸(12-HEPE)、15-羟基二十碳五烯酸(15-HEPE)、5-氧代二十碳四烯酸(5-KETE)等水平降低(P<0.05);与模型组比较,桃红方高剂量组干预后23个代谢物水平升高(P<0.05)。结论 桃红方可改善高盐血瘀证大鼠的血液流变学异常和血管损伤;其机制可能与调控ALOX5介导的多不饱和脂肪酸代谢、抑制NF-κB炎症信号及恢复纤溶平衡相关。 |
| 关键词: 血瘀证|桃红方|代谢组学|网络药理学|花生四烯酸5-脂加氧酶|多不饱和脂肪酸 |
| DOI:10.3969/j.issn.1674-070X.2026.10.004 |
| 投稿时间:2026-07-06 |
| 基金项目:国家自然科学基金项目(8237432);湖南省自然科学基金高校联合基金项目(2026JJ30079);湖南中医药大学交叉学科方向培育项目(2025JC0201)。 |
|
| Metabolomics-based study on the ameliorative effects of Taohong Formula on rats with high-salt diet-induced blood stasis |
| LIANG Ting, DENG Yunfang, ZHONG Hui, LIU Qin, CHEN Guangyu, LI Liang |
| (Hunan Engineering Technology Research Center for Medicinal and Functional Food, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;Key Laboratory of TCM Heart and Lung Pattern Identification & Medicated Diet and Dietotherapy, Changsha, Hunan 410208, China;Hunan Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China) |
| Abstract: |
| Objective To investigate the ameliorative effects and underlying mechanisms of Taohong Formula on rats with high-salt diet-induced blood stasis. Methods Ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS/MS) was used to identify the chemical constituents of Taohong Formula. A total of 36 male SD rats were randomly divided into blank group, model group, low-, medium-, and high-dose Taohong Formula groups, and aspirin group, with 6 rats in each group. A blood stasis model was established by feeding the rats a high-salt diet. The modeling period lasted 30 days, and drug administration began on the 17th day of modeling. Each treatment group received the corresponding drug by gavage for 14 days. Blood stasis manifestations, including tongue color, tail color, and claw color, were observed. Whole blood viscosity, plasma viscosity, and fibrinogen levels were measured by hemorheological testing, and histopathological changes in the coronary arteries were examined by HE staining. Network pharmacology was used to predict the active ingredients of Taohong Formula and targets associated with blood stasis pattern, and a protein-protein interaction (PPI) network was constructed. Key signaling pathways involved in the ameliorative effects of Taohong Formula on blood stasis pattern were identified by GO and KEGG enrichment analyses. Serum metabolomics analysis was performed using UPLC-Q-TOF-MS/MS to identify differential metabolites and enrich key metabolic pathways. A "metabolite-target gene" regulatory network was then constructed. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), thrombomodulin (TM), nuclear factor κB subunit 1 (NF-κB1), serine protease inhibitor family E member 1 (SERPINE1), matrix metalloproteinase-9 (MMP-9), epidermal growth factor receptor (EGFR), nitric oxide (NO), and albumin (ALB). Immunohistochemistry was used to detect the protein expression levels of arachidonate 5-lipoxygenase (ALOX5) and nuclear factor κB (NF-κB) in cardiac and renal tissues. Results Taohong Formula was identified as containing 71 constituents, including flavonoids and organic acids. Compared with the blank group, rats in the model group exhibited blood stasis manifestations, including a dark purple tongue and subcutaneous ecchymosis. Whole blood viscosity (at low, medium, and high shear rates), plasma viscosity, and fibrinogen levels were significantly increased (P<0.001). Histopathological examination revealed thickening of the intima and media of the coronary arteries, an increase in the luminal diameter, detachment of the intima and adventitia, disorganized cellular arrangement, and edema of myocardial fibroblasts. Serum levels of IL-6, TNF-α, ICAM-1, VCAM-1, TM, NF-κB1, SERPINE1, MMP-9, and EGFR were significantly increased (P<0.001), NO levels were increased (P<0.05), and ALB levels were significantly decreased (P<0.001). The protein expression levels of ALOX5 and NF-κB in cardiac and renal tissues were significantly increased (P<0.001). Compared with the model group, rats in the low-, medium-, and high-dose Taohong Formula groups and the aspirin group all exhibited varying degrees of improvement in tongue color and in blood stasis manifestations of the tail and claws. Whole blood viscosity (at low, medium, and high shear rates), plasma viscosity, and fibrinogen levels were significantly decreased (P<0.001). Serum levels of IL-6, TNF-α, EGFR, MMP-9, NF-κB1, ICAM-1, VCAM-1, SERPINE1, and TM were significantly decreased in all four treatment groups (P<0.05, P<0.01, or P<0.001). ALB levels were increased in the low- and high-dose Taohong Formula groups (P<0.001), whereas ALB and NO levels were decreased in the aspirin group (P<0.05 and P<0.01, respectively). The protein expression levels of ALOX5 and NF-κB in cardiac and renal tissues were significantly decreased in all four treatment groups (P<0.01 or P<0.001). Compared with the low-dose Taohong Formula group, whole blood viscosity (at low, medium, and high shear rates), plasma viscosity, and fibrinogen levels were significantly decreased in the medium- and high-dose Taohong Formula groups (P<0.05). Serum levels of IL-6, TNF-α, EGFR, NF-κB1, ICAM-1, and SERPINE1 were significantly decreased in the medium- and high-dose Taohong Formula groups and the aspirin group (P<0.05, P<0.01, or P<0.001). MMP-9 levels were significantly increased in the aspirin group (P<0.05), whereas ALB levels were significantly decreased in the medium-dose Taohong Formula group and the aspirin group (P<0.001). VCAM-1 and TM levels were significantly decreased in the high-dose Taohong Formula group and the aspirin group (P<0.01 or P<0.001), and NO levels were significantly decreased in the aspirin group (P<0.001). The protein expression levels of ALOX5 and NF-κB in cardiac and renal tissues were significantly decreased in the medium- and high-dose Taohong Formula groups and the aspirin group (P<0.01 or P<0.001). Compared with the medium-dose Taohong Formula group, serum levels of IL-6, TNF-α, EGFR, NF-κB1, ICAM-1, VCAM-1, and SERPINE1 were significantly decreased in the high-dose Taohong Formula group and the aspirin group (P<0.05, P<0.01, or P<0.001). ALB levels were significantly increased in the high-dose Taohong Formula group (P<0.001), whereas MMP-9 levels were significantly decreased in this group (P<0.05). TM and NO levels were significantly decreased in the aspirin group (P<0.01 and P<0.001, respectively). The protein expression levels of ALOX5 and NF-κB in cardiac and renal tissues were significantly decreased in the high-dose Taohong Formula group and the aspirin group (P<0.05, P<0.01, or P<0.001). Compared with the high-dose Taohong Formula group, serum levels of IL-6, TNF-α, ALB, ICAM-1, VCAM-1, TM, and NO were significantly decreased in the aspirin group (P<0.05, P<0.01, or P<0.001), whereas MMP-9 levels were significantly increased (P<0.001). ALOX5 protein expression in cardiac tissue was significantly decreased in the aspirin group (P<0.05), and NF-κB protein expression in renal tissue was significantly decreased (P<0.01). Network pharmacology identified 178 common targets of Taohong Formula and blood stasis pattern, which were enriched in signaling pathways including lipid and atherosclerosis and the phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) pathway. Metabolomics identified 24 differential metabolites. Compared with the blank group, the levels of eicosapentaenoic acid (EPA) and its downstream metabolites, including 5-hydroxyeicosapentaenoic acid (5-HEPE), 12-hydroxyeicosapentaenoic acid (12-HEPE), 15-hydroxyeicosapentaenoic acid (15-HEPE), and 5-oxoeicosatetraenoic acid (5-KETE), were significantly decreased in the model group (P<0.05). Compared with the model group, the levels of 23 metabolites were significantly increased in the high-dose Taohong Formula group after intervention (P<0.05). Conclusion Taohong Formula can ameliorate hemorheological abnormalities and vascular injury in rats with high-salt diet-induced blood stasis pattern. The underlying mechanism may involve regulating ALOX5-mediated polyunsaturated fatty acid metabolism, inhibiting NF-κB inflammatory signaling, and restoring fibrinolytic balance. |
| Key words: blood stasis pattern|Taohong Formula|metabolomics|network pharmacology|arachidonate 5-lipoxygenase|poly-unsaturated fatty acids |
|
 二维码(扫一下试试看!) |
|
|
|
|